MAD2L2 and colorectal carcinoma: Genetic inhibition of REV7 significantly improved sensitivity to 5-FU and cisplatin in vivo and in vitro, thereby highlighting the therapeutic potential of inhibiting REV7 in chemoresistant CRC therapy.